Matthew Caufield
Stock Analyst at H.C. Wainwright
(4.28)
# 1,193
Out of 5,074 analysts
342
Total ratings
41.2%
Success rate
9.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MLYS Mineralys Therapeutics | Reiterated: Buy | $56 | $21.47 | +160.83% | 22 | Oct 23, 2026 | |
| FDMT 4D Molecular Therapeutics | Reiterated: Buy | $36 | $11.85 | +203.80% | 35 | Oct 22, 2026 | |
| IMUX Immunic | Reiterated: Buy | $22 | $7.22 | +204.71% | 18 | Oct 22, 2026 | |
| ZBIO Zenas BioPharma | Reiterated: Buy | $44 | $28.27 | +55.64% | 19 | Oct 13, 2026 | |
| KOD Kodiak Sciences | Reiterated: Buy | $96 → $126 | $85.78 | +46.89% | 19 | Oct 12, 2026 | |
| ALDX Aldeyra Therapeutics | Reiterated: Hold | $2 | $0.6453 | +209.93% | 34 | Sep 30, 2026 | |
| SRZN Surrozen | Reiterated: Buy | $44 → $54 | $25.75 | +109.71% | 11 | Sep 25, 2026 | |
| DMAC DiaMedica Therapeutics | Reiterated: Buy | $12 | $8.63 | +39.05% | 14 | Sep 21, 2026 | |
| PHAT Phathom Pharmaceuticals | Reiterated: Buy | $26 | $7.01 | +270.90% | 22 | Sep 21, 2026 | |
| IRD Opus Genetics | Reiterated: Buy | $8 | $3.82 | +109.42% | 37 | Sep 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $36 | $2.99 | +1,104.01% | 3 | Sep 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $38 | $3.25 | +1,069.23% | 18 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $3.20 | +462.50% | 8 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $88 | $72.08 | +22.09% | 11 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $0.5622 | +967.24% | 13 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $6 | $1.02 | +488.24% | 13 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.024 | n/a | 10 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.92 | n/a | 20 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $9 | $9.60 | n/a | 9 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $39 | $7.17 | n/a | 1 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $75.03 | n/a | 5 | Oct 21, 2022 |
Mineralys Therapeutics
Oct 23, 2026
Reiterated: Buy
Price Target: $56
Current: $21.47
Upside: +160.83%
4D Molecular Therapeutics
Oct 22, 2026
Reiterated: Buy
Price Target: $36
Current: $11.85
Upside: +203.80%
Immunic
Oct 22, 2026
Reiterated: Buy
Price Target: $22
Current: $7.22
Upside: +204.71%
Zenas BioPharma
Oct 13, 2026
Reiterated: Buy
Price Target: $44
Current: $28.27
Upside: +55.64%
Kodiak Sciences
Oct 12, 2026
Reiterated: Buy
Price Target: $96 → $126
Current: $85.78
Upside: +46.89%
Aldeyra Therapeutics
Sep 30, 2026
Reiterated: Hold
Price Target: $2
Current: $0.6453
Upside: +209.93%
Surrozen
Sep 25, 2026
Reiterated: Buy
Price Target: $44 → $54
Current: $25.75
Upside: +109.71%
DiaMedica Therapeutics
Sep 21, 2026
Reiterated: Buy
Price Target: $12
Current: $8.63
Upside: +39.05%
Phathom Pharmaceuticals
Sep 21, 2026
Reiterated: Buy
Price Target: $26
Current: $7.01
Upside: +270.90%
Opus Genetics
Sep 8, 2026
Reiterated: Buy
Price Target: $8
Current: $3.82
Upside: +109.42%
Sep 2, 2026
Reiterated: Buy
Price Target: $36
Current: $2.99
Upside: +1,104.01%
Aug 12, 2026
Reiterated: Buy
Price Target: $38
Current: $3.25
Upside: +1,069.23%
Aug 7, 2026
Reiterated: Buy
Price Target: $18
Current: $3.20
Upside: +462.50%
Aug 7, 2026
Reiterated: Buy
Price Target: $88
Current: $72.08
Upside: +22.09%
Aug 6, 2026
Reiterated: Buy
Price Target: $6
Current: $0.5622
Upside: +967.24%
Aug 4, 2026
Reiterated: Buy
Price Target: $8 → $6
Current: $1.02
Upside: +488.24%
Aug 22, 2025
Rated: Hold
Price Target: n/a
Current: $0.024
Upside: n/a
May 27, 2025
Rated: Hold
Price Target: n/a
Current: $2.92
Upside: n/a
May 19, 2025
Reiterated: Hold
Price Target: $9
Current: $9.60
Upside: n/a
Oct 29, 2024
Reiterated: Buy
Price Target: $39
Current: $7.17
Upside: n/a
Oct 21, 2022
Rated: Hold
Price Target: n/a
Current: $75.03
Upside: n/a